{"id":8138,"date":"2021-12-16T12:19:55","date_gmt":"2021-12-16T17:19:55","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/vapreotidacetat-rc-160-cas-103222-11-3-behandling-for-akut-blodning-i-matstrupen-variceal\/"},"modified":"2021-12-16T12:19:55","modified_gmt":"2021-12-16T17:19:55","slug":"vapreotidacetat-rc-160-cas-103222-11-3-behandling-for-akut-blodning-i-matstrupen-variceal","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/sv\/product\/vapreotidacetat-rc-160-cas-103222-11-3-behandling-for-akut-blodning-i-matstrupen-variceal\/","title":{"rendered":"Vapreotidacetat\/RC 160 CAS 103222-11-3 Behandling F\u00f6r akut bl\u00f6dning i matstrupen variceal"},"content":{"rendered":"

Vapreotidacetat\/RC 160 CAS 103222-11-3 Behandling F\u00f6r akut bl\u00f6dning i matstrupen variceal<\/strong><\/h2>\n

Produktnamn: VAPREOTIDE
\nSynonymer: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (disulfidbrygga Cys2-Cys7);HD-Phe-Cys-Tyr-D -Trp-Lys-Val-Cys-Trp-NH2;D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-CONH2(disulfid Cys2-Cys7);Vapreotid, RC-160;RC-160 ;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2;FCYWKVCW-NH2
\nCAS: 103222-11-3
\nMF: C57H70N12O9S2
\nMW: 1131.
\nEINECS:
\nProduktkategorier: Somatostatinreceptor
\nMol Fil: 103222-11-3.mol<\/p>\n

H3Pharma har f\u00f6rv\u00e4rvat den v\u00e4rldsomsp\u00e4nnande forskningsutvecklings- och kommersiella licensen f\u00f6r vaptan fr\u00e5n Debiopharm i Schweiz. 2001 New England Journal of Medicine rapporterade formuleringen med omedelbar fris\u00e4ttning, som var kliniskt testad och bevisad av Chemicalbook f\u00f6r tidig anv\u00e4ndning vid behandling av akut matstrupe. \u00c5r 2004 utvecklade och tillverkade Debiopharms dotterbolag, den kanadensiska cancer- och endokrinologispecialisten H3Pharma, ett nytt l\u00e4kemedel .<\/p>\n

Vapreotide Acetate\/ RC 160 CAS 103222-11-3 Kemiska egenskaper<\/strong>
\nKokpunkt 1540,9\u00b165,0 \u00b0C(F\u00f6rutsp\u00e5dd)
\ndensitet 1,40\u00b10,1 g\/cm3(F\u00f6rutsp\u00e5dd)
\nlagring temp. \u221220\u00b0C
\npka 9,90\u00b10,15(f\u00f6rutsp\u00e5dd)<\/p>\n

Funktion och till\u00e4mpning av Vapreotide Acetate\/RC 160 CAS 103222-11-3<\/strong>
\n1. Formuleringen f\u00f6r omedelbar fris\u00e4ttning av Sanvar, en somatostatinanalog , anv\u00e4nds vid behandling av akut esofageal variceal bl\u00f6dning (EVB).
\n2.Sanvar anv\u00e4nds f\u00f6re endoskopisk intervention f\u00f6r att kontrollera bl\u00f6dning och f\u00f6rhindra \u00e5terbl\u00f6dning under de kritiska fem dagarna efter bl\u00f6dningens b\u00f6rjan. EVB \u00e4r ett livshotande tillst\u00e5nd och d\u00f6dligheten \u00e4r h\u00f6g (cirka 15 % till 25 %) under de f\u00f6rsta sex veckorna efter bl\u00f6dningen. EVB \u00e4r orsaken till cirka 70 % av gastrointestinala bl\u00f6dningar hos patienter som lider av levercirrhos.
\n3. Sanvar (vapreotidacetat) \u00e4r en syntetisk oktapeptidanalog av det naturligt f\u00f6rekommande somatostatinhormonet. Det har liknande farmakologiska egenskaper som naturligt somatostatin, men uppvisar en l\u00e4ngre verkningstid. Det \u00e4r den enda somatostatinanalogen som har visat statistiskt signifikanta f\u00f6rdelar vid tidig behandling av EVB i samband med endoskopisk terapi, i en placebokontrollerad klinisk studie (Cal\u00e8s et al. New England Journal of Medicine, 2001). Kontroll av bl\u00f6dning med \u00f6verlevnad efter fem dagar uppn\u00e5ddes oftare med Sanvar (p=0,021) \u00e4n med placebo. Ytterligare<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktnamn: VAPREOTIDE
\nCAS: 103222-11-3
\nMF: C57H70N12O9S2
\nMW: 1131.37
\nMol Fil: 103222-11-3.mol<\/p>\n","protected":false},"featured_media":2133,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[527],"product_tag":[1534],"class_list":{"0":"post-8138","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-andra-peptider","7":"product_tag-vapreotide-acetate-rc-160-cas-103222-11-3-treatment-for-acute-esophageal-variceal-bleeding-sv","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product\/8138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/comments?post=8138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media\/2133"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media?parent=8138"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_brand?post=8138"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_cat?post=8138"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_tag?post=8138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}